MTOR and acute myeloid leukemia: This concentration was chosen because mTOR signaling in primary AML cells is often inhibited by rapamycin 10–20 nM, but for exceptional patients there is a partial resistance, and concentrations exceeding 50 nM have to be used to achieve a reduction in downstream protein phosphorylation [18].